{"entity":{"id":"nct05210790","kind":"trial","name":"A Phase 3 Study of Rusfertide in Patients With Polycythemia Vera","aka":[],"tldr":"A phase 3 trial of Rusfertide in myeloproliferative neoplasms, run by Protagonist Therapeutics, Inc., active and no longer recruiting.","summary":"A Phase 3 Study of Rusfertide in Patients With Polycythemia Vera is a phase 3 interventional study registered as NCT05210790 by Protagonist Therapeutics, Inc., with 293 participants enrolled, started 2022-04-01 and due to reach its primary completion in 2025-02-21. Interventions recorded: Placebo and Rusfertide.","status":"active","asOf":"2026-09-16","links":[{"label":"ClinicalTrials.gov NCT05210790","url":"https://clinicaltrials.gov/study/NCT05210790"}],"tags":["pipeline","ctgov-ingest"],"related":[],"cancers":["myeloproliferative-neoplasms"],"sections":[],"technologies":[],"targets":[],"drugs":["rusfertide"],"companies":["protagonist-therapeutics"],"institutions":[],"pathways":[],"terms":[],"trials":[],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"notes":[],"nct":"NCT05210790","phase":"3","setting":"A Phase 3 Study of the Hepcidin Mimetic Rusfertide (PTG-300) in Patients With Polycythemia Vera","sponsor":"Protagonist Therapeutics, Inc.","enrolled":293,"outcomes":[]},"route":"/trials/nct05210790/","neighbours":{"cancer":[{"id":"myeloproliferative-neoplasms","kind":"cancer","name":"Myeloproliferative neoplasms (PV, ET, myelofibrosis)","route":"/cancers/myeloproliferative-neoplasms/"}],"drug":[{"id":"rusfertide","kind":"drug","name":"Rusfertide","route":"/drugs/rusfertide/"}],"company":[{"id":"protagonist-therapeutics","kind":"company","name":"Protagonist Therapeutics","route":"/companies/protagonist-therapeutics/"}]}}